Are Radiometal-Labeled Antibodies Better Than Iodine-131–Labeled Antibodies: Comparative Pharmacokinetics and Dosimetry of Copper-67–, Iodine-131–, and Yttrium-90–Labeled Lym-1 Antibody in Patients with Non-Hodgkin's Lymphoma
- 1 September 2000
- journal article
- Published by Elsevier in Clinical Lymphoma
- Vol. 1 (2) , 118-126
- https://doi.org/10.3816/clm.2000.n.010
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's LymphomaJournal of Clinical Oncology, 1999
- Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1998
- Low-dose, Fractionated Radioimmunotherapy for B-cell Malignancies using131I-LYM-1 AntibodyCancer Biotherapy & Radiopharmaceuticals, 1998
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.Journal of Clinical Oncology, 1996
- Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomasThe Lancet, 1995
- Processing of antibody-radioisotope conjugates after binding to the surface of tumor cellsCancer, 1994
- A comparison of67Cu- and131I-labelled forms of monoclonal antibodies SEN7 and SWA20 directed against small-cell lung cancerInternational Journal of Cancer, 1994
- Treatment of Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Selection of radionuclides for radioimmunotherapyMedical Physics, 1993